Pediatric Dermatitis and Psoriasis Treatment

Introduction to Treatment Approaches

The American Academy of Dermatology recommends careful monitoring for children 0-6 years and infants who are vulnerable to HPA axis suppression due to their high body surface area-to-volume ratio, when using topical corticosteroids 1
Limited quantities of high-potency steroids should be prescribed with clear application instructions to prevent overuse and adverse effects, as suggested by the American Academy of Dermatology 1

Topical Therapies

Topical calcineurin inhibitors like tacrolimus 0.1% are recommended for facial and genital psoriasis in children, according to the American Academy of Dermatology 1, 2
Topical calcineurin inhibitors have shown excellent improvement in facial and inverse psoriasis within 30 days in pediatric patients, as reported by the American Academy of Dermatology 2

Combination and Rotational Therapies

Combination therapy using topical vitamin D analogs with topical corticosteroids is effective for plaque psoriasis, as recommended by the American Academy of Dermatology 3
Rotational therapy alternating between different topical agents can serve as a steroid-sparing approach to reduce adverse effects, according to the American Academy of Dermatology 4

Phototherapy and Systemic Therapies

Narrowband UVB phototherapy is recommended for moderate to severe pediatric plaque and guttate psoriasis, as suggested by the American Academy of Dermatology 5, 6
Methotrexate is the most common systemic medication used for moderate to severe pediatric psoriasis, according to the American Academy of Dermatology 5

Safety Considerations

Rebound flares are a significant risk when high-potency corticosteroids are abruptly discontinued, as noted by the American Academy of Dermatology 1
Regular monitoring by a dermatologist is essential to ensure proper use and prevent adverse effects in children receiving topical corticosteroids, as recommended by the American Academy of Dermatology 1
Long-term maintenance should use the lowest effective dose with the least toxic therapy, according to the American Academy of Dermatology 6

Age-Specific Considerations

Infants and young children (0-6 years) are particularly vulnerable to HPA axis suppression due to their high body surface area-to-volume ratio, as reported by the American Academy of Dermatology 1
High-potency or ultra-high-potency topical corticosteroids should be used with extreme caution in infants and young children, as suggested by the American Academy of Dermatology 1
For adolescents approaching childbearing potential, certain medications like tazarotene and acitretin should be avoided or used with strong caution due to teratogenicity risks, according to the American Academy of Dermatology 4, 7

Hydrocortisone Cream Use in Infants

Appropriate Potency Selection

The American Academy of Dermatology recommends using low-potency corticosteroids, such as hydrocortisone 1% or 2.5% cream, for infants, as high-potency or ultra-high-potency topical corticosteroids should be avoided entirely in infants and young children 8
Class V/VI corticosteroids, including hydrocortisone 2.5%, are specifically recommended for facial application in pediatric patients, according to the American Academy of Dermatology 8

Alternative and Adjunctive Therapies

The American Academy of Dermatology suggests that topical calcineurin inhibitors, such as tacrolimus 0.1%, may be preferred for facial or genital area rashes in infants to avoid corticosteroid-related risks 9
The use of emollients and moisturizers alongside topical corticosteroids is recommended by the American Academy of Dermatology to enhance efficacy and reduce the need for prolonged steroid use 10, 11

Psoriasis Treatment in Pediatric Patients

Topical Therapy for Mild to Moderate Psoriasis

The American Academy of Dermatology recommends the use of calcipotriol/betametasone dipropionate combination therapy applied once daily for up to 4 weeks for children aged 12 years and older with mild to moderate plaque psoriasis (Recommendation strength B, evidence level I-II) 12, 13, 14
For scalp psoriasis, calcipotriol/betametasone dipropionate suspension applied once daily for up to 8 weeks is recommended for children aged 12 years and older (Recommendation strength B, evidence level II) 12, 13, 14
In clinical studies, 58% of pediatric patients (12-17 years) achieved disease clearance of the scalp after 8 weeks, with good tolerability 12, 14
Initial pruritus (65% of patients) significantly reduced to 10% by the end of treatment 12, 14

Topical Therapy for Sensitive Areas

The American Academy of Dermatology recommends the use of tacrolimus 0.1% ointment as off-label monotherapy for pediatric psoriasis of the face and genital area (Recommendation strength C, evidence level II-III) 15
In studies of children with facial or inverse psoriasis, clearance or excellent improvement was achieved within 30 days in 88% of patients who continued treatment 15
Complete clearance of facial psoriasis was achieved within 72 hours with tacrolimus 0.1% in a case series 15

Rotational Therapy and Steroid-Sparing

The American Academy of Dermatology recommends considering rotational therapy with topical vitamin D analogs, topical calcineurin inhibitors, emollients, tar-based therapies, and topical corticosteroids as a steroid-sparing regimen in children (Recommendation strength C, evidence level II) 12, 13, 14
A common approach involves applying topical corticosteroids on weekends and calcitriol topical on weekdays after the initial 2 weeks of combination therapy 15
The use of emollients (at the same time or at different times of the day) with calcipotriene topical may be considered to reduce irritation and improve efficacy (Recommendation strength C) 12, 13, 14

Monitoring and Safety Considerations

The American Academy of Dermatology recommends monitoring vitamin D metabolites during therapy with calcipotriene/calcipotriol when applied to large body surface areas (Recommendation strength B, evidence level I-II) 16
At any age, vitamin D analogs should be used with caution in patients with calcium metabolism disorders or kidney disease 12, 13
The American Academy of Dermatology recommends avoiding the use of acitretin or using it with extreme caution in adolescent females due to the risk of teratogenicity 14

Pediatric Psoriasis Treatment Guidelines

First-Line Topical Therapy

The American Academy of Dermatology recommends a combination therapy of calcipotriol/betametasone dipropionate applied once daily for up to 4 weeks as a safe and effective treatment for mild-moderate pediatric psoriasis in children aged 12 years and above 17, 18, 19
For sensitive areas (face and genitalia), tacrolimus 0.1% ointment is recommended as off-label monotherapy for pediatric psoriasis 17
Complete clearance of facial psoriasis was achieved within 72 hours in case series 17

Rotational Therapy and Steroid-Sparing

The American Academy of Dermatology suggests considering rotational therapy with topical vitamin D analogs, topical calcineurin inhibitors, emollients, tar-based therapies, and topical corticosteroids as a steroid-sparing regimen to reduce potential adverse effects from excessive reliance on topical steroid therapy in children 18, 19

Topical Vitamin D Analog Monitoring

Monitoring of vitamin D metabolites during therapy with calcipotriol/calcipotriol is recommended when applied to large areas of the body surface 18
The application of calcipotriol should be limited to small areas of the body 18
Maximum recommended dosages to prevent hypercalcemia: 50 g/week/m² for calcipotriol and 100 g/week/m² for calcipotriol 18

Adjuvant Therapies

The use of emollients (concurrently or at different times of the day) with topical calcipotriol may be considered to reduce irritation and improve efficacy 18, 19
Pre-treatment of involved skin with 6-10% salicylic acid for 1 week may improve the efficacy of subsequent monotherapy with calcipotriol 19

Topical Steroid Use in Infants

Critical Age-Specific Considerations

Infants aged 0-6 years, particularly those under 2 months, are uniquely vulnerable to HPA axis suppression because of their thin, highly absorptive skin and disproportionately high body surface area-to-volume ratio compared to older children and adults, as recommended by the American Academy of Dermatology 20

Recommended Approach for 2-Month-Olds

Potency Selection

Limit treatment to Class V/VI/VII corticosteroids only (hydrocortisone 1% or 2.5% cream), as recommended by the American Academy of Dermatology 21

Application Guidelines

Prescribe limited quantities with explicit instructions on amount and application sites to prevent overuse, as recommended by the American Academy of Dermatology 20

Duration and Monitoring

Avoid unsupervised continuous use; gradual reduction following clinical response is recommended, as suggested by the American Academy of Dermatology 21
Assess growth parameters in infants requiring long-term topical corticosteroid therapy, as recommended by the American Academy of Dermatology 21

Critical Safety Warnings

Documented Risks in Infants

HPA axis suppression can occur even with medium-potency steroids when used on large body surface areas or under occlusion, as reported by the American Academy of Dermatology 20, 21

Common Pitfalls to Avoid

Abrupt discontinuation of even low-potency steroids can cause rebound flares, though this is more concerning with higher potency agents, as noted by the American Academy of Dermatology 20

Safety and Efficacy of Desonide Lotion in Infants

Critical Age-Specific Risks and Monitoring

Infants aged 0-6 years are at substantially greater risk of HPA axis suppression than older children due to their disproportionately high body surface area-to-volume ratio, according to the Journal of Microbiology, Immunology and Infection 22, 23
The American Academy of Pediatrics and other guideline societies recommend avoiding use on the face, neck, and skin folds when possible, as these areas have increased absorption; if facial treatment is necessary, consider topical calcineurin inhibitors as an alternative 22, 23

Comparison to Other Low-Potency Options

The Taiwan guidelines specifically recommend that infants and young children should be treated with less potent topical corticosteroids than older children, making desonide an appropriate choice in this potency range, with a classification as a Class VI low-potency topical corticosteroid, comparable to hydrocortisone 2.5% 22, 23

Hydrocortisone Butyrate Therapy for Eczema or Dermatitis

Application and Safety Considerations

For facial or genital involvement, consider switching to tacrolimus 0.1% ointment instead of hydrocortisone butyrate to avoid corticosteroid-related atrophy risks in these sensitive areas, as recommended by the American Academy of Dermatology 24
Avoid abrupt discontinuation of hydrocortisone butyrate after prolonged use, and instead taper gradually to prevent rebound flares, according to the American Academy of Dermatology 24

Alternative or Adjunctive Therapy

If there is an inadequate response to hydrocortisone butyrate after 2 weeks, reassess and consider increasing to a potent topical corticosteroid or adding topical calcineurin inhibitors for face or genitals, as suggested by the European Society for Medical Oncology 25, 26

Management of Moderate Atopic Dermatitis in Children with Medium‑Potency Topical Corticosteroids

Pharmacologic Options

Fluticasone propionate cream/ointment is recommended by the Taiwan guideline for proactive therapy in children with moderate‑to‑severe atopic dermatitis, applied to the trunk and extremities. 27
Mometasone furoate cream/ointment is endorsed for twice‑weekly proactive maintenance therapy for up to 16 weeks in pediatric moderate‑severe disease. 27

Acute Flare Management

Apply a medium‑potency corticosteroid (fluticasone or mometasone) once or twice daily to affected trunk and extremities until lesions show significant improvement; this regimen is safe for up to 12 weeks of active disease control. 27
Do not exceed twice‑daily applications, as higher frequency does not increase efficacy and raises the risk of adverse effects. 28
Reassess the child after 2 weeks; if there is no clinical improvement, evaluate for secondary Staphylococcus aureus infection and consider systemic antibiotics (e.g., flucloxacillin) or escalation of therapy. 28

Proactive Maintenance After Control

Once acute lesions are controlled, transition to twice‑weekly application of fluticasone or mometasone on previously affected sites to maintain remission. 27
This proactive schedule may be continued for up to 16 weeks and has been shown to reduce relapse rates in moderate‑severe pediatric atopic dermatitis. 27

Site‑Specific Modifications

Facial, neck, and intertriginous areas should avoid medium‑potency steroids because of higher absorption and risk of atrophy; instead use low‑potency agents (e.g., hydrocortisone 2.5 %) or calcineurin inhibitors such as tacrolimus 0.03 % ointment. 27
Trunk and extremities tolerate medium‑potency agents safely for prolonged periods, making them appropriate sites for both acute and maintenance therapy. 27
Occlusive dressings and large‑area applications should be avoided to minimize systemic absorption and HPA‑axis suppression. 27

Adjunctive Therapies

Regular emollient use provides both short‑ and long‑term steroid‑sparing benefits in moderate disease. Apply emollients immediately after a 10–15 minute lukewarm bath to maximize skin hydration. Ointment‑type emollients give the greatest occlusive effect for very dry skin. 27
Wet‑wrap therapy with a medium‑potency corticosteroid can be employed for 3–7 days (maximum 14 days) when standard topical treatment fails, serving as an effective second‑line option before systemic immunosuppressants. 27

Safety Monitoring

In pre‑adolescent children (≈11 years), the risk of hypothalamic‑pituitary‑adrenal (HPA) axis suppression from medium‑potency steroids is lower than in younger children (0–6 years) due to a more favorable body‑surface‑area‑to‑volume ratio. 27
Prescribe limited quantities with clear instructions on amount and application sites, and educate caregivers to avoid inadvertent over‑use.

Common Pitfalls to Avoid

Using high‑potency steroids on the face leads to irreversible atrophy and telangiectasia; always opt for low‑potency steroids or calcineurin inhibitors in these regions. 27
Applying steroids more than twice daily does not improve outcomes and increases adverse‑effect risk. 28
Neglecting emollient therapy reduces the steroid‑sparing effect and may increase the need for higher‑potency steroids. 27
Overlooking secondary bacterial infection can delay healing; persistent disease despite appropriate therapy warrants evaluation for Staphylococcus aureus and possible systemic antibiotics. 28

Management of Plaque Psoriasis in Children ≤ 6 Years (American Academy of Dermatology Guidelines)

1. Initial Topical Therapy

Start low‑potency corticosteroid (hydrocortisone 1–2.5 %) applied twice daily to trunk and extremities, combined with liberal use of thick, ointment‑based emollients. This regimen is recommended as first‑line for toddlers because they are at highest risk for hypothalamic‑pituitary‑adrenal (HPA) axis suppression; low‑potency steroids minimize systemic absorption. 29
Use topical tacrolimus 0.1 % ointment twice daily for facial or genital involvement instead of any corticosteroid. Tacrolimus produces clearance within 3 days to 2 weeks and avoids steroid‑related atrophy in sensitive areas. 29
Prescribe only small‑quantity tubes and give explicit instructions on the amount to apply per site to prevent overtreatment and systemic toxicity. 29
Avoid medium‑potency or higher potency steroids in children ≤ 6 years because of unacceptable risk of systemic absorption and HPA‑axis suppression. 29

2. Adjunctive and Steroid‑Sparing Strategies

Emollients (ointment‑based) should be applied liberally throughout the day, especially after a lukewarm bath, to provide a steroid‑sparing effect and reduce irritation from active agents. [29][30]
If no adequate response after 2 weeks, add topical vitamin D analog (calcipotriene 0.005 % ointment) once daily to non‑facial lesions. Use emollients together with calcipotriene to lessen stinging and burning. [29][30]
Rotational therapy: alternate low‑potency corticosteroid on weekends with calcipotriene on weekdays to further limit steroid exposure; this approach is endorsed by the American Academy of Dermatology for pediatric psoriasis. 30
Do not combine salicylic acid with calcipotriene concurrently; the acidic pH inactivates calcipotriene. If both are needed, apply salicylic acid at least one week before initiating calcipotriene. 30

3. Monitoring, Safety, and Tapering

Infants and toddlers (0–6 years) are uniquely vulnerable to systemic corticosteroid absorption even with low‑potency agents; avoid applying to >20 % body surface area and never use occlusive dressings. 29
Do not abruptly discontinue corticosteroids after >2 weeks of use. Taper by reducing frequency (daily → every other day → twice weekly) over 1–2 weeks, then transition to maintenance therapy. 29
Schedule a follow‑up visit at 2 weeks to assess clinical response and check for adverse effects. If calcipotriene is used on large areas, consider monitoring serum calcium and vitamin D metabolites. 29
Regular dermatology follow‑up is essential to ensure proper technique, prevent overuse, and reinforce education. 29

4. Second‑Line Topical Option: Short‑Contact Anthralin

Apply short‑contact anthralin 0.1–0.25 % for 15–30 minutes daily, then wash off. Concentration can be doubled gradually, up to 1–2 %, as tolerated. [31][32]
Efficacy: Approximately 70 % of pediatric patients achieve a good response, with a mean remission duration of about 5.5 months. 31
Safety warnings: Severe skin irritation occurs in ~63 % of patients, and the drug stains skin and clothing brown‑purple. Use only after other topical agents have failed and before considering phototherapy or systemic therapy. 31

5. Referral to Pediatric Dermatology

Refer when there is failure to respond to appropriate topical therapy after 6–8 weeks or when disease involves >20 % of body surface area. [31][32]
Referral is also indicated for severe pruritus affecting sleep or development, or when phototherapy or systemic agents become necessary. (clinical judgment)

All statements are derived from American Academy of Dermatology guideline recommendations and supporting evidence cited in the referenced literature.